相关临床试验
77
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1846
进行中（未招募）
1
1.3%
已完成
64
83.1%
终止
7
9.1%
Unknown
1
1.3%
撤回
4
5.2%
暂无批准数据
- The University at Buffalo received $5 million from the State University of New York to lead a statewide, multi-campus research network on age-related brain disorders. - The award is part of $10 million in New York State funding supporting the SUNY Brain Institute, with UB designated anchoring hub for its inaugural module. - UB will serve as hub for three years, coordinating shared-access, governance, data-integration and operational infrastructure across five SUNY institutions. - The network aims to accelerate development of new biomarkers, therapeutic targets and approaches to diagnosis, treatment and prevention of neurological disease.
- The National Institutes of Health has awarded the National Crystallization Center at the University at Buffalo a five-year, $5.5 million grant to continue advancing structural biology research. - The award builds on the center's initial 2021 NIH funding, which established the NCC at UB-HWI as an NIH National Resource serving a national user base. - Since 2021, the NCC has supported approximately 475 users from 238 academic research groups across 133 institutions in 34 states and four countries. - The center's high-throughput crystallization capabilities have enabled structural determination of treatments for nicotine addiction, SARS-CoV-2 inhibitors, and drug-resistance targets in metastatic cancer.
- Monomethyl auristatin E (MMAE), a potent chemotherapy payload used in antibody-drug conjugates, causes peripheral neuropathy in roughly 50% of treated patients, sometimes requiring dose reduction or treatment discontinuation. - University at Buffalo researchers received more than $410,000 from the National Cancer Institute to investigate why MMAE causes nerve damage and how it might be prevented. - The two-year study will examine whether modulating permeability glycoprotein (P-gp) can reduce neurotoxicity, using animal models that mimic human genetic deficiencies and drug interactions. - Findings could enable new or repurposed drugs to prevent neuropathy, allowing patients to maintain full dosages and avoid long-term quality-of-life impairment.
- Researchers at the University at Buffalo received a $2 million, four-year NHLBI grant to develop a safer, more effective ARDS treatment using omega-3 fatty acids. - The approach delivers DHA via liposome nanoparticles to neutrophils in the lungs, where the LOX5/15 enzyme converts it into inflammation-resolving molecules called resolvins. - ARDS affects more than 200,000 people annually in the U.S., with a mortality rate of 30–50%, and current steroid-based therapies are not always successful and raise infection risk. - If successful, the neutrophil-targeting strategy could represent a paradigm shift for treating inflammatory diseases beyond ARDS, including autoimmune diseases, arthritis, and Crohn's disease.
- Nine UB faculty-founded startups have collectively raised nearly $16 million since the start of 2025 from NIH, NSF, U.S. Army, CEPI, and NYSTAR. - Research-based spinouts span diverse areas including low-cost blood tests for brain aneurysms, surgical AI, smartphone hearing assessments, and more. - UB's Business and Entrepreneur Partnerships (BEP) provides commercialization support, technology transfer, incubator space, and early-stage funding to de-risk deep tech ventures. - UB reports $571 million in annual research spending, ranking as the No. 1 public university in New York State for research activity.
- Radiation for head and neck cancers leaves nearly every patient with painful mouth inflammation and ulcers, with severe cases interfering with eating, drinking, or treatment itself. - Female patients appear to experience more severe oral mucositis, a finding supported by laboratory studies showing female mice develop markedly worse radiation damage than males. - Keith Kirkwood, DDS, PhD, received a $440,000 two-year grant from the National Institute of Dental and Craniofacial Research to uncover the biological causes of this sex-based difference. - The team will use single-cell RNA-sequencing and multimodal spectral flow cytometry to identify potential therapeutic targets for radiation-induced oral mucositis.
- The University at Buffalo's Community Health Equity Research Institute (CHERI) has distributed more than $600,000 in grants to East Side community organizations and researchers. - Funding, sourced from an NIH National Institute for Minority Health and Health Disparities grant, supports projects addressing social determinants of health such as housing, food access, and workforce training. - Ten community organizations received grants for initiatives ranging from home renovations and community garden rejuvenation to youth leadership and health equity ambassador programs. - A pilot studies program provides seed funding for early career researchers conducting community-based participatory research to generate preliminary data for future federal funding applications.
- University at Buffalo chemists developed a method using blue LED light and a photocatalyst to modify two adjacent carbon atoms in a single reaction instead of the usual one. - The technique uses off-the-shelf blue LEDs and commercially available carbon-halogen bond building blocks familiar from undergraduate organic chemistry. - Visible light offers a milder alternative to UV light, reducing the risk of degrading sensitive organic molecules during synthesis. - The team plans to collaborate with pharmaceutical companies to tailor the method for specific drug targets, aiming to accelerate production of more complex small-molecule drugs.
- A UB-led team developed AI-based image processing methods that detect previously invisible gray matter (cortical) lesions on conventional legacy MRI scans, publishing findings in Communications Medicine. - Applying the new multimodal cortical lesion enhancement (MMCLE) technique to over 700 participants from the phase III ORATORIO trial of Ocrelizumab revealed 15–20 cortical lesions per patient, totaling more than 11,000 across the dataset. - Cortical lesions are key indicators of MS disease progression and cognitive impairment but have been undetectable on standard clinical MRI, frustrating clinicians for decades. - The breakthrough enables retrospective analysis of past clinical trial data and promises to improve future MS drug development and patient monitoring.
- Brian Tsuji, PharmD, an internationally recognized NIH-funded clinician-scientist, assumed the deanship at the University of Colorado Anschutz Skaggs School of Pharmacy and Pharmaceutical Sciences in January. - Tsuji brings a "Dream Big" philosophy and aims to elevate the school into the top five pharmacy schools in the United States through collaborative, interdisciplinary "team science." - His research lab, relocating from the University at Buffalo, focuses on developing new therapeutics against antimicrobial-resistant "superbugs" and is supported by two large NIH R01 grants. - Tsuji previously led the creation of the nation's first Master's in Clinical and Translational Therapeutics and authored international consensus dosing guidelines for polymyxin antibiotics.
